Talon Drops on FDA Review of Cancer Therapy: San Francisco Mover

Talon Therapeutics Inc. fell the most since November 2010 after the U.S. Food and Drug Administration said it wants more time to review information about Talon’s Marqibo blood-cancer treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.